Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04211259 | Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization | recruiting | Early Phase 1 | 70 | Rutgers, The State University of New JerseyOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04508790 | Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 |
| NCT05418088 | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | recruiting | Phase 1 | 54 | Sumithira VasuOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | recruiting | Phase 2 | 31 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07541391 | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease(KOALA) | recruiting | Phase 1 | 12 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608978 | Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes(Pola-ZRCHP) | recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609030 | A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma | recruiting | N/A | 90 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07609576 | Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies. | recruiting | — | 350 | Infanta Leonor University HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | recruiting | Phase 1 / Phase 2 | 115 | Stephan Grupp MD PhDOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07052916 | A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties | recruiting | N/A | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05616325 | Long-term Ovarian Fertility in Patients Treated for Lymphoma.(FERTILymph) | recruiting | — | 270 | University Hospital, LilleOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | recruiting | Phase 2 | 100 | Reid Merryman, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07138209 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 228 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT05011045 | Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06098430 | Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) | recruiting | — | 100 | St. Jude Children's Research HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06433947 | Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 130 | Opna Bio LLCINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT04941716 | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial | recruiting | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05853965 | Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma(BELI(E)VE) | recruiting | Phase 1 / Phase 2 | 45 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06005870 | Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression | recruiting | Phase 2 | 41 | Huazhong University of Science and TechnologyOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06867536 | Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden(GLOHRT-01) | recruiting | Phase 2 | 40 | Liling ZhangOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05794880 | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | recruiting | N/A | 40 | Medical College of WisconsinOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05828511 | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment(LINKER-MM4) | recruiting | Phase 1 / Phase 2 | 149 | Regeneron PharmaceuticalsINDUSTRY | 3 | May 13, 2026 | clinicaltrials |
| NCT06993675 | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)(ROTATE) | recruiting | Phase 2 | 50 | Noffar BarOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07259070 | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07261163 | Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | recruiting | Phase 2 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07299149 | Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma(ZGR in TN FL) | recruiting | Phase 2 | 34 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | recruiting | Phase 2 | 300 | RenJi HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07283224 | Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma | recruiting | — | 600 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07579234 | A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 3 | 261 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT07582354 | MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity | recruiting | — | 520 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07582432 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma(SIGMA) | recruiting | Phase 3 | 49 | Grifols Biologicals, LLCINDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT05018520 | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk | recruiting | Phase 3 | 640 | Ruijin HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05645510 | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study(LONGEVITI) | recruiting | — | 75 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07554898 | Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma | recruiting | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07577206 | Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia. | recruiting | Early Phase 1 | 10 | National Cancer Institute, NaplesOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | recruiting | Phase 1 / Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07377435 | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT02269592 | Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | recruiting | — | 10,000 | Dana-Farber Cancer InstituteOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06799026 | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 25 | David AviganOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06022939 | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | recruiting | Phase 3 | 338 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT07448935 | One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS(ALPS) | recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05099471 | Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia(VIWA-1) | recruiting | Phase 2 | 80 | Christian BuskeOTHER | 2 | May 5, 2026 | clinicaltrials |
| NCT05529069 | Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05848765 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy(REFRACT) | recruiting | Phase 2 | 284 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06822829 | Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma(REVERSE_2021) | recruiting | — | 50 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 29, 2026source: clinicaltrials